These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37528320)

  • 1. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
    Sun SH; Angell CD; Savardekar H; Sundi D; Abood D; Benner B; DiVincenzo MJ; Duggan M; Choueiry F; Mace T; Trikha P; Lapurga G; Johnson C; Carlson EJ; Chung C; Peterson BR; Lianbo Yu ; Zhao J; Kendra KL; Carson WE
    Cancer Immunol Immunother; 2023 Nov; 72(11):3461-3474. PubMed ID: 37528320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
    Savardekar H; Allen C; Jeon H; Li J; Quiroga D; Schwarz E; Wu RC; Zelinskas S; Lapurga G; Abreo A; Stiff A; Shaffer J; Blaser BW; Old M; Wesolowski R; Xin G; Kendra KL; Chung D; Carson WE
    Mol Cancer Res; 2024 Mar; 22(3):308-321. PubMed ID: 38015751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
    Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
    Sagiv-Barfi I; Kohrt HE; Czerwinski DK; Ng PP; Chang BY; Levy R
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E966-72. PubMed ID: 25730880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
    Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
    Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
    Deng G; He J; Huang Q; Li T; Huang Z; Gao S; Xu J; Wang T; Di J
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.
    Kim C; Park JH; Choi YJ; Jun HO; Chung JK; Park TK; Yoon JS; Yang JW; Jang SY
    Front Endocrinol (Lausanne); 2024; 15():1420024. PubMed ID: 39280007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
    Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
    Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.